相关实验视频

Updated: Jan 16, 2026

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV

Published on: September 14, 2010

设计,开发和评估针对KSHV相关疾病的基因疗法

Tomoki Inagaki¹, Jonna Magdallene Espera¹, Kang-Hsin Wang¹

¹Department of Dermatology, School of Medicine, the University of California, Davis (UC Davis), 3301 C-street, Sacramento, CA 95816, USA.

Molecular therapy. Oncology

|October 2, 2025

概括

一种新型腺相关病毒 (AAV) 基因治疗载体选择性地向卡波西肉瘤相关疹病毒 (KSHV) 感染的细胞. 这种针对KSHV的治疗消除癌细胞并防止病毒复制,副作用最小.

科学领域:

在瘤学瘤学.
病毒学病毒学
基因治疗基因治疗

背景情况:

卡波西肉瘤相关的疹病毒 (KSHV) 导致卡波西肉瘤和B细胞淋巴增殖性疾病.
编码KSHV的延迟关联核抗原 (LANA) 对于病毒基因组维护至关重要,并且在KSHV感染的癌细胞中表达,使其成为治疗点.

研究的目的:

使用腺相关病毒 (AAV) 开发一种癌症基因疗法载体,该载体专门针对KSHV感染的细胞.
为了利用KSHV的延迟相关核抗原 (LANA) 和终端重复 (TR) 功能,用于向基因表达和癌细胞根除.

主要方法:

设计了一种AAV载体 (AAV8-TR2-OriP-TK) 结合KSHV终端重复 (TR) 和一个可诱导的Lytic促进剂,在KSHV感染的细胞中选择性地表达胺激酶 (TK).
将AAV8-TR2-OriP-TK接着甘西克洛维尔 (GCV) 给KSHV感染细胞和异种移植瘤模型.
研究了AAV8-TR2-OriP-TK/GCV与已知可重新激活KSHV的抗癌药物的协同作用.

主要成果:

AAV8-TR2-OriP-TK/GCV有效地根除了KSHV感染的细胞,包括干细胞衍生的上皮细胞,而不损害非感染的细胞.
该载体抑制了从重新激活的细胞中产生KSHV病毒的产生,并与抗癌药物协同作用,以提高治疗疗效.
在异种移植模型中,治疗抑制了KSHV感染的瘤生长,并且没有从全身AAV给药中检测到的副作用.

结论:

针对KSHV的AAV介导基因疗法为治疗KSHV驱动的癌症提供了一个有前途的策略.
开发的载体系统证明了选择性的癌细胞杀死和病毒复制抑制.
这种方法有可能在未来针对疹病毒相关的恶性瘤的治疗干预中发挥作用.

关键词:

卡波西的肉瘤是卡波西的肉瘤.卡波西的肉瘤相关的疹病毒.MT: 定期发行定期发行腺相关病毒的病毒.癌症基因治疗癌症基因治疗瘤性疹病毒病毒瘤治疗疗法瘤治疗疗法促进者-增强剂的相互作用.终端重复的重复

更多相关视频

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Quantitative Fluorescence In Situ Hybridization FISH and Immunofluorescence IF of Specific Gene Products in KSHV-Infected Cells

Quantitative Fluorescence In Situ Hybridization FISH and Immunofluorescence IF of Specific Gene Products in KSHV-Infected Cells

Published on: August 27, 2019

相关概念视频

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...